April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Doctors Debate: Should Maintenance Therapy Be Included in the Treatment of Acute Myeloid Leukemia?
October 20th 2021Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.
Read More
Testing Strategies for Identifying Eosinophilia in Patients With Myeloid/Lymphoid Neoplasms
October 16th 2021In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.
Read More
FDA Approval Sought for Beti-Cel to Treat B-Thalassemia Requiring Transfusions
September 22nd 2021A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.
Read More
FDA Grants Priority Review to Abatacept to Prevent Moderate to Severe Acute GVHD
August 23rd 2021The FDA has accepted the supplemental biologics license application for abatacept and granted it priority review for the prevention of moderate to severe acute graft versus host disease in patients 6 years of age and older receiving unrelated donor hematopoietic stem cell transplantation.
Read More